Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3949/ccjm.55.3.257 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The exceptionally rare phenomenon of well-differentiated colon neuroendocrine tumors.
J Neuroendocrinol
January 2025
Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Colonic neuroendocrine tumors (NETs), excluding rectal NETs, are often described as relatively common and aggressive, with inferior median survival compared with other gastrointestinal (GI) primary sites. However, epidemiological databases may conflate well-differentiated NETs with poorly differentiated neuroendocrine carcinomas (NECs), leading to a lack of precise data on the prevalence, clinical behavior, and prognosis of well-differentiated colonic NETs. We analyzed a large institutional database to identify patients with well-differentiated NETs originating in the colon, excluding rectal NETs.
View Article and Find Full Text PDFA phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Oncologist
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.
Methods: We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET.
Impact of lymph node involvement in pulmonary carcinoids: a narrative review.
Transl Lung Cancer Res
December 2024
Department of Thoracic Surgery, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Background And Objective: Pulmonary carcinoids (PCs) represent a rare subset of neuroendocrine tumors (NETs) within the respiratory tract that exhibit unique characteristics and clinical behaviors. These tumors are currently staged according to the tumor-nodules-metastases (TNM) classification of non-small cell lung cancer (NSCLC), which brings their reliability into question. The aim of this study was to assess reliability of the current TNM staging of PCs and explore other relevant prognostic factors of patient outcomes.
View Article and Find Full Text PDFAtypical Small Cell Lung Cancer: A New Malignancy Characterized by Chromothripsis, Carcinoid Tumors, and Wild-type RB1 and TP53.
Cancer Discov
January 2025
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas.
Small cell lung cancer (SCLC) and pulmonary carcinoid tumors are traditionally seen as unrelated, with SCLC linked to smoking and characterized by biallelic loss of RB1 and TP53 and rapid progression. Rekhtman and colleagues upend these assumptions by discovering an "atypical" SCLC that arises in nonsmokers with intact RB1 and TP53 loci, chromothripsis-induced oncogene amplifications on extrachromosomal DNA, and frequent synchronous carcinoid tumors. See related article by Rekhtman et al.
View Article and Find Full Text PDFSafety and Efficacy of Transsternal Core Biopsy of Anterior Mediastinal Masses.
Ann Thorac Surg Short Rep
December 2024
Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Background: The study evaluated the safety and adequacy of percutaneous transsternal anterior mediastinal core biopsy.
Methods: All percutaneous computed tomography-guided transsternal mediastinal 18-gauge core biopsies performed at 2 academic centers were retrospectively reviewed. Procedural, clinical, and pathology data were recorded.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!